Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-63623872 plus oseltamivir in hospitalized adults and elderly patients with influenza A
NL-OMON46300Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Influenza A infection comparing JNJ-63623872 + oseltamivir with Placebo + oseltamivir (2 arms). Primary endpoint: Pharmacokinetic parameters of JNJ-63623872. Started Jan 2017; status: active, not recruiting.
02
Drugs
pimodiviroseltamivir
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on NL-OMON46300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46300.